Enhertu（DS-8201）

On December 20, 2019, AstraZeneca and Daiichi Sankyo announced that the FDA of the US Food and Drug Administration had accelerated the approval of Enhertu (Famr-Trastuzumab Deruxtecan-NXKI, DS-8201) for the treatment of unresectable or metastatic HER2-positive breast cancer patients who had previously received two or more anti-HER2-based regimens in metastatic environment.

Enhertu(DS-8201)_ Hong Kong Jimin Pharmaceutical
【 Indications and uses of Enhertu(DS-8201) 】
Enhertu is a conjugate of antibody against HER2 and topoisomerase inhibitor, which is suitable for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more previous anti-HER2-based treatment schemes in metastatic environment.

【 Enhertu(DS-8201) Dosage and Administration Method 】
■ Do not replace ENHERTU with trastuzumab or a new trastuzumab-Metatron conjugate.
■ The recommended dose of ■Enhertu is 5.4 mg/kg, and it is given intravenously once every 3 weeks (21-day cycle) until the disease progresses or unacceptable toxicity appears.
■ First infusion
● The infusion time is more than 90 minutes.
■ Subsequent infusion
● If the previous infusion is well tolerated, the infusion time is more than 30 minutes.
● If the patient has symptoms related to infusion, please slow down or interrupt the infusion speed.
● In case of serious infusion reaction, please stop using Enhertu permanently.
■ If the planned dose is delayed or missed, please give it as soon as possible; Don’t wait for the next planned cycle. Adjust the administration plan to maintain the 3-week interval between two administrations. Infusion was carried out at the dose and rate tolerated by the patient in the last infusion.

[Adverse reaction of Enhertu(DS-8201)]
The most common adverse reactions are interstitial lung disease/pneumonia, neutropenia and left ventricular dysfunction.

Note: If there is any new packaging for drugs, the new packaging shall prevail. The above information comes from the Internet or translated by student volunteers in medical colleges and universities (if there are any mistakes or omissions, please help me to correct them). It is for internal discussion of medical staff only, without any basis for medication. Please consult the attending physician for specific medication guidelines.